Development and validation of a proprietary medium formulation for recombinant subunit vaccines by the Baculovirus Expression Vector System (BEVS)
June 17-22, 2018
Insect cells & baculovirus expression vector system (BEVS) is an efficient platform for the production of baculovirus vectors and the expression of recombinant proteins or VLPs (Virus Like Particles). This technology is increasingly used in large-scale manufacturing of human and veterinary vaccines. The production of safe and cost-effective vaccines requires the development of animal origin free and low-cost culture media supporting strong insect cell growth, high yield of baculovirus and sustained expression of recombinant proteins or VLPs.
In this context, Boehringer-Ingelheim decided to develop its own animal origin free media (with similar or better performance than the commercial one) in collaboration with NRC and suppliers. The different steps, feedback and results will be presented in this poster.
Catherine Cleuziat,; Sophie Biard; Chloé Damiany; Sylvain Lagresle; Christine Coupier; Amine Kamen; Hervé Poulet; Noël Detraz; Zahia Hannas; Géraldine Popovic; Chun Fang Shen; and Amine Kamen, "Development and validation of a proprietary medium formulation for recombinant subunit vaccines by the Baculovirus Expression Vector System (BEVS)" in "Vaccine Technology VII", Amine Kamen, McGill University Tarit Mukhopadhyay, University College London Nathalie Garcon, Bioaster Charles Lutsch, Sanofi Pasteur Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/vt_vii/63